Cost-Effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek …

K Athanasakis, E Karampli, D Tsounis, A Bilitou… - Clinical drug …, 2015 - Springer
Abstract Background and Objectives Three new oral anticoagulants (NOACs) are currently
approved for stroke prevention and systemic embolism in patients with non-valvular atrial …
被引用次数：10 相关文章

Cost-Effectiveness of Apixaban vs. Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis on Patients with Non-Valvular Atrial Fibrillation in the …

K Athanasakis, E Karampli, D Tsounis, A Bilitou… - Clinical Drug …, 2015 - infona.pl
Background and Objectives Three new oral anticoagulants (NOACs) are currently approved
for stroke prevention and systemic embolism in patients with non-valvular atrial fibrillation …

Cost-Effectiveness of Apixaban vs. Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis on Patients with Non-Valvular Atrial Fibrillation in the …

K Athanasakis, E Karampli, D Tsounis… - Clinical Drug …, 2015 - search.proquest.com
Abstract Background and Objectives Three new oral anticoagulants (NOACs) are currently
approved for stroke prevention and systemic embolism in patients with non-valvular atrial …
[PDF] academia.edu

[PDF][PDF] Cost-Effectiveness of Apixaban vs. Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis on Patients with Non-Valvular Atrial Fibrillation in …

K Athanasakis, E Karampli, D Tsounis, A Bilitou… - 2015 - academia.edu
Abstract Background and Objectives Three new oral anticoagulants (NOACs) are currently
approved for stroke prevention and systemic embolism in patients with non-valvular atrial …

Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek …

K Athanasakis, E Karampli, D Tsounis… - Clinical Drug …, 2015 - europepmc.org
Methods A Markov model that evaluated clinical events, quality-adjusted life expectancy,
and costs for patients treated with apixaban or other NOACs formed the basis of the …
[PDF] researchgate.net

[PDF][PDF] Cost-Effectiveness of Apixaban vs. Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis on Patients with Non-Valvular Atrial Fibrillation in …

K Athanasakis, E Karampli, D Tsounis, A Bilitou… - 2015 - researchgate.net
Abstract Background and Objectives Three new oral anticoagulants (NOACs) are currently
approved for stroke prevention and systemic embolism in patients with non-valvular atrial …

Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek …

K Athanasakis, E Karampli, D Tsounis… - Clinical drug …, 2015 - pubmed.ncbi.nlm.nih.gov
Background and objectives Three new oral anticoagulants (NOACs) are currently approved
for stroke prevention and systemic embolism in patients with non-valvular atrial fibrillation …
[PDF] academia.edu

[PDF][PDF] Cost-Effectiveness of Apixaban vs. Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis on Patients with Non-Valvular Atrial Fibrillation in …

K Athanasakis, E Karampli, D Tsounis, A Bilitou… - 2015 - academia.edu
Abstract Background and Objectives Three new oral anticoagulants (NOACs) are currently
approved for stroke prevention and systemic embolism in patients with non-valvular atrial …

[引用][C] Cost-Effectiveness of Apixaban vs. Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis on Patients with Non-Valvular Atrial Fibrillation in …

K Athanasakis, E Karampli, D Tsounis… - Clinical drug …, 2015 - Adis International